Open navigation
Search
Search

Select your region

Life Sciences & Healthcare

Latest

  • Transposition Time Updates – Nordic Trio: Denmark, Finland, and Sweden Progress Towards New EU Product Liability Directive Implementation
    12 Feb 2026 6 min read
  • From political parties to kitchens and concert stages: the legal stakes behind the name “Anders”
    23 Jan 2026 4 min read
  • Medical technologies in defence and aerospace: Key themes and emerging questions in regulation
    09 Jan 2026 7 min read
  • Positive and negative pointers in clinical trial prior art: diverging inventive step outcomes at the EPO and UPC
    08 Jan 2026 13 min read
With over 480 international specialist lawyers across CMS and the support of the Lifesciences Asia-Pacific Network (LAN), we understand the scientific and commercial as well as the legal imperatives affecting your lifesciences and healthcare business.

We work with and have established long-term relationships with the top 100 lifesciences and healthcare companies in the areas of pharmaceuticals, medical devices, biotechnology, agriculture and food.

Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics. As members and partners of major industry associations such as the ABPI, ABHI, BIVDA, PAGB, EFPIA and EUCOMED we help shape the legal frameworks impacting the lifesciences and healthcare sectors. 

We regularly advise our clients on their day-to-day operational needs such as, patent enforcement, commercial and clinical trial agreements, protection of privacy and trade secrets, e-health, support with advertisement and promotion of medicine, public sector procurement, pricing and reimbursement as well as regulatory advice. 

Equally, when you need specialist advice in the area of lifesciences and healthcare for strategic agreements, planning a corporate transaction or embarking on litigation (whether product liability or otherwise), we have a team that is well versed in the industry issues to help you.

Awards & Recognitions
01
  • Quote
    "Well known for its strength in advising on the full range of public procurement and competition-related work."
    Legal 500, 2025
  • Quote
    "Very hands-on knowledge and ability to provide very practical examples to the business. Feedback received was really what we needed, being very hands on, easy to understand feedback to specific practical questions."
    Feedback from a client about the department - Legal 500, 2022
  • Quote
    "CMS' cross-practice collaboration and multilingual capabilities make it a popular choice for a varied roster of pharmaceutical heavyweights, industry associations and hospital groups. The team is especially renowned for its public procurement capabilities, working with some of the largest Europe-wide governing bodies on high-profile, cross-border projects. Joint practice heads Bruno Fonteyn and Virginie Dor are noted for their expertise in health sector regulation and EU-wide health and social care procurement mandates, respectively."
    Legal 500, 2022

Life Sciences & Healthcare Insights

Transposition Time Updates – Nordic Trio: Denmark, Finland, and Sweden Progress Towards New EU Product Liability Directive Implementation

12 Feb 2026 6 min read

From political parties to kitchens and concert stages: the legal stakes behind the name “Anders”

23 Jan 2026 4 min read

Medical technologies in defence and aerospace: Key themes and emerging questions in regulation

09 Jan 2026 7 min read

Positive and negative pointers in clinical trial prior art: diverging inventive step outcomes at the EPO and UPC

08 Jan 2026 13 min read

Digital health apps and telemedicine: Updated CMS Expert Guide for 30 jurisdictions

01 Dec 2025 2 min read

Transposition Time – Update on the EU Member States’ adoption of the new Product Liability Directive

17 Nov 2025 6 min read

Beyond disclosure: how the EU Pay Transparency Directive will reshape employer obligations

17 Sep 2025 6 min read

A phase III clinical trial protocol does not by itself provide a reasonable expectation of success of the investigated treatment (T 122/23)

20 Aug 2025 15 min read

Events

  • Belgium
    08 Apr 2026

    CMS at Fordham IP & Policy Conference

  • Belgium
    21 Apr 2026

    On the Pulse webinar series 2026 - Spring/Summer

  • Belgium
    28 Apr 2026

    IP Insights webinar series 2026

  • Belgium
    02 May 2026

    CMS at INTA 2026

Back to top Back to top
Warning: Fraudulent emails and messages